Company intelligence / Profile preview

Mito US One

Haifa, Israel

Ownership: Private
Development stage: Other

Overview

Early clinical trials show that MNV-201 improves weight, mobility, kidney function, and hematologic stability in patients with Pearson Syndrome and MDS, with no drug-related adverse effects; received FDA Fast Track and Rare Pediatric Designation

Therapeutic areas: OtherHematologyRare Diseases
Modalities: Cell therapyBiologic
Industry: Biotech

Partnerships

Launch One Acquisition Corp.global longevity clinic partnerships (planned)

Beyond the preview

Go deeper on Mito US One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mito US One.

Explore the full profile